RxDoctor Payments Data

Cheryl Cooper

Psychiatric/Mental Health · Jackson, MSNPI 1174302830

Payments from drug & device makers

$1,818in general payments, 2019–2025

Across 69 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$385
  • Axsome Therapeutics, Inc.$338
  • Indivior Inc.$306
  • Vanda Pharmaceuticals Inc.$245
  • Otsuka America Pharmaceutical, Inc.$224
  • Supernus Pharmaceuticals, Inc.$166
  • plus $156 from 4 others

What the payments were for

  • Food & beverage$1,818100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,818 in reported general payments places this provider in the 70th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$43,051
Medicare patients
59
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$45,915
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl265$30,761
SuboxoneBuprenorphine Hcl/Naloxone Hcl50$19,842
ZubsolvBuprenorphine Hcl/Naloxone Hcl19$11,638
Clonazepam81$790
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$785
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$674
Gabapentin49$560
Lurasidone Hcl14$504
Bupropion Hcl12$496
Aripiprazole13$459
Quetiapine Fumarate32$450
Fluoxetine Hcl29$436
Naltrexone Hcl12$382
Trazodone Hcl51$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$89$45,91512 claims
Indivior Inc.Suboxone$306$19,84250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →